Downregulating the Canonical Wnt/β-catenin Signaling Pathway Attenuates the Susceptibility to Autism-like Phenotypes by Decreasing Oxidative Stress

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2012 Mar 1

PMID 22374471

Citations 38

Authors

Yinghua Zhang

Yan Sun

Fei Wang

Zhongping Wang

Yuwen Peng

Ruixi Li

Affiliations

Soon will be listed here.

Abstract

Although a growing body of evidence supports the importance of the Wnt/β-catenin signaling pathway and oxidative stress in the pathogenesis of autism, it is unclear whether a relationship exists between the Wnt/β-catenin pathway and oxidative homeostasis. The present study examines the effects of sulindac, a small molecule inhibitor of the Wnt/β-catenin signaling pathway, on the oxidative status of rats that are prenatally exposed to valproic acid (VPA), which is used in an animal model of autism. Our data show that sulindac treatment downregulated the canonical Wnt/β-catenin signaling pathway by enhancing the expression of Glycogen Synthase Kinase 3β and attenuating the expression of β-catenin in comparison to levels in VPA-treated rats. Concomitantly, a marker of lipid peroxidation, 4-hydroxynonenal, was reduced as well. Sulindac treatment ameliorated the pain threshold, repetitive/stereotypic activity, learning and memory abilities and behavioral abnormalities of rats in our autism model. Our working model suggests that the upregulation of the Wnt/β-catenin signaling pathway induced by VPA administration during early pregnancy produces an imbalance of oxidative homeostasis that facilitates susceptibility to autism. This information may be instrumental in designing appropriate therapeutic regimens with small molecule inhibitors of the Wnt/β-catenin pathway for the treatment of autism-like behavioral phenotypes.

Citing Articles

Unraveling the Role of Wnt Signaling Pathway in the Pathogenesis of Autism Spectrum Disorder (ASD): A Systematic Review.

Bou Najm D, Alame S, Takash Chamoun W Mol Neurobiol. 2024; 62(4):4971-4992.

PMID: 39489840 DOI: 10.1007/s12035-024-04558-x.

Impairments of social interaction in a valproic acid model in mice.

Ukezono M, Kasahara Y, Yoshida C, Murakami Y, Okada T, Takano Y Front Behav Neurosci. 2024; 18:1430267.

PMID: 39267983 PMC: 11390364. DOI: 10.3389/fnbeh.2024.1430267.

Shielding Effect of Ryanodine Receptor Modulator in Rat Model of Autism.

Kumar H, Kulkarni G, Diwan V, Sharma B Basic Clin Neurosci. 2023; 14(2):247-261.

PMID: 38107532 PMC: 10719969. DOI: 10.32598/bcn.2021.2966.1.

Three Decades of Valproate: A Current Model for Studying Autism Spectrum Disorder.

Zarate-Lopez D, Torres-Chavez A, Galvez-Contreras A, Gonzalez-Perez O Curr Neuropharmacol. 2023; 22(2):260-289.

PMID: 37873949 PMC: 10788883. DOI: 10.2174/1570159X22666231003121513.

Dysregulation of the Wnt/β-catenin signaling pathway via Rnf146 upregulation in a VPA-induced mouse model of autism spectrum disorder.

Park G, Jang W, Kim S, Gonzales E, Ji J, Choi S Exp Mol Med. 2023; 55(8):1783-1794.

PMID: 37524878 PMC: 10474298. DOI: 10.1038/s12276-023-01065-2.

References

Ciani L, Salinas P . WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci. 2005; 6(5):351-62. DOI: 10.1038/nrn1665. View

Lemjabbar-Alaoui H, Dasari V, Sidhu S, Mengistab A, Finkbeiner W, Gallup M . Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS One. 2006; 1:e93. PMC: 1762353. DOI: 10.1371/journal.pone.0000093. View

Lu W, Tinsley H, Keeton A, Qu Z, Piazza G, Li Y . Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol. 2008; 602(1):8-14. PMC: 2637082. DOI: 10.1016/j.ejphar.2008.10.053. View

Chauhan A, Chauhan V, Brown W, Cohen I . Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins. Life Sci. 2004; 75(21):2539-49. DOI: 10.1016/j.lfs.2004.04.038. View

Clay H, Sillivan S, Konradi C . Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci. 2010; 29(3):311-24. PMC: 3010320. DOI: 10.1016/j.ijdevneu.2010.08.007. View

Zhang B, Wang X, Nazarali A . Ascorbic acid reverses valproic acid-induced inhibition of hoxa2 and maintains glutathione homeostasis in mouse embryos in culture. Cell Mol Neurobiol. 2009; 30(1):137-48. PMC: 11498376. DOI: 10.1007/s10571-009-9438-7. View

Tsujino N, Nakatani Y, Seki Y, Nakasato A, Nakamura M, Sugawara M . Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism. Neurosci Res. 2006; 57(2):289-95. DOI: 10.1016/j.neures.2006.10.018. View

Stokstad E . Development. New hints into the biological basis of autism. Science. 2001; 294(5540):34-7. DOI: 10.1126/science.294.5540.34. View

Landrigan P . What causes autism? Exploring the environmental contribution. Curr Opin Pediatr. 2010; 22(2):219-25. DOI: 10.1097/MOP.0b013e328336eb9a. View

10.

Blaxill M, Baskin D, Spitzer W . Commentary: Blaxill, Baskin, and Spitzer on Croen et al. (2002), the changing prevalence of autism in California. J Autism Dev Disord. 2003; 33(2):223-6; discussion 227-9. DOI: 10.1023/a:1022912115365. View

11.

Schneider T, Przewlocki R . Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology. 2004; 30(1):80-9. DOI: 10.1038/sj.npp.1300518. View

12.

Brault V, MOORE R, Kutsch S, Ishibashi M, Rowitch D, McMahon A . Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development. 2001; 128(8):1253-64. DOI: 10.1242/dev.128.8.1253. View

13.

Dufour-Rainfray D, Vourch P, Le Guisquet A, Garreau L, Ternant D, Bodard S . Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett. 2009; 470(1):55-9. DOI: 10.1016/j.neulet.2009.12.054. View

14.

Yao J, Reddy R, VAN KAMMEN D . Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001; 15(4):287-310. DOI: 10.2165/00023210-200115040-00004. View

15.

Sajdel-Sulkowska E, Xu M, McGinnis W, Koibuchi N . Brain region-specific changes in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD). Cerebellum. 2010; 10(1):43-8. DOI: 10.1007/s12311-010-0223-4. View

16.

Bromley R, Mawer G, Clayton-Smith J, Baker G . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008; 71(23):1923-4. DOI: 10.1212/01.wnl.0000339399.64213.1a. View

17.

James S, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O . Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009; 23(8):2374-83. PMC: 2717775. DOI: 10.1096/fj.08-128926. View

18.

Evatt M, DeLong M, Grant W, Cannell J, Tangpricha V . Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2009; 73(12):997. DOI: 10.1212/WNL.0b013e3181af0b95. View

19.

Villagonzalo K, Dodd S, Dean O, Gray K, Tonge B, Berk M . Oxidative pathways as a drug target for the treatment of autism. Expert Opin Ther Targets. 2010; 14(12):1301-10. DOI: 10.1517/14728222.2010.528394. View

20.

Chenn A, Walsh C . Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in beta-catenin overexpressing transgenic mice. Cereb Cortex. 2003; 13(6):599-606. DOI: 10.1093/cercor/13.6.599. View